Covagen's Uniqueness

Covagen is a clinical stage company that develops bispecific FynomAbs by fusing its human Fynomer® binding proteins to antibodies, resulting in therapeutics with novel modes of action and enhanced efficacy. Our current pipeline is focussed on the treatment of inflammatory diseases and cancer. The ability to fuse Fynomers to multiple sites on an antibody allows Covagen to create FynomAbs with tailored architectures to maximize efficacy.

More About Us >>

Pipeline Highlights

Covagen is developing COVA322 for the treatment of inflammatory diseases such as rheumatoid arthritis and psoriatic arthritis. COVA322 is a bispecific FynomAb® inhibiting TNF and IL-17A. COVA322 is currently investigated in a Phase Ib/IIa clinical trial.

More About COVA322 >>

News & Events

Janssen Affiliate Cilag GmbH International Acquires Covagen AG
Janssen Affiliate Cilag GmbH International Acquires Covagen AG
Clinical Candidate COVA 322 and FynomAb® Technology Platform Further Strengthen Immunology Portfolio and Capabilities

More News & Events >>